SBI-183
SBI-183 is an orally active inhibitor of QSOX1 (Kd: 20 μM) . SBI-183 suppresses the proliferative and invasive phenotype of renal cancer cell lines, including triple negative breast cancer cell line, lung adenocarcinoma cell line and pancreatic ductal adenocarcinoma. SBI-183 inhibits tumor growth in two human xenograft mouse models of renal cell carcinoma in vivo [1].
Product Specifications
CAS Number
625403-59-0
UNSPSC
12352005
Target
Transmembrane Glycoprotein
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sbi-183.html
Purity
99.8
Smiles
O=C(C1=CC(OC)=CC=C1)NC2=CC=C(N3CCCC3)C=C2
Molecular Formula
C18H20N2O2
Molecular Weight
296.36
References & Citations
[1]Fifield, et al. Molecular Inhibitor of QSOX1 Suppresses Tumor Growth In Vivo. Molecular cancer therapeutics. 2020, 19 (1), 112–122.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Rabbit Anti Human DRP1 Polyclonal Affinity Purified (PBS with 0.05% Proclin300 and 50% glycerol, pH7.4.) (Western Blot)